Atoltivimab/maftivimab/odesivimab

Atoltivimab/maftivimab/odesivimab
Combination of
Atoltivimab	Monoclonal antibody
Maftivimab	Monoclonal antibody
Odesivimab	Monoclonal antibody
Clinical data
Trade names	Inmazeb
Other names	REGN-EB3
AHFS/Drugs.com	Monograph
License data	US DailyMed: Inmazeb;
Routes of; administration	Intravenous
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2500649-90-9;
KEGG	D11922;

Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus).^[2] It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.^[2]

The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection.^[2]^[3]

Atoltivimab/maftivimab/odesivimab is the first FDA-approved treatment for Zaire ebolavirus.^[2] Atoltivimab/maftivimab/odesivimab was approved for medical use in the United States in October 2020.^[2]^[4]^[5]^[3]^[6] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[7] It is on the World Health Organization's List of Essential Medicines.^[8]

^ "Inmazeb- atoltivimab, maftivimab, and odesivimab-ebgn injection, solution". DailyMed. Retrieved 17 January 2021.
^ ^a ^b ^c ^d ^e ^f Cite error: The named reference FDA PR was invoked but never defined (see the help page).
^ ^a ^b "Drug Trials Snapshots: Inmazeb". U.S. Food and Drug Administration. 14 October 2020. Retrieved 23 October 2020. This article incorporates text from this source, which is in the public domain.
^ "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.
^ "Inmazeb: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 15 October 2020.
^ "Drug Approval Package: Inmazeb". U.S. Food and Drug Administration. 12 November 2020. Retrieved 23 December 2020.
^ "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[Inmazeb_FDA_label-1] "Inmazeb- atoltivimab, maftivimab, and odesivimab-ebgn injection, solution". DailyMed. Retrieved 17 January 2021.

[FDA_PR-2] ^ ^a ^b ^c ^d ^e ^f Cite error: The named reference FDA PR was invoked but never defined (see the help page).

[FDA_snapshot-3] "Drug Trials Snapshots: Inmazeb". U.S. Food and Drug Administration. 14 October 2020. Retrieved 23 October 2020. This article incorporates text from this source, which is in the public domain.

[4] "Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)". Regeneron Pharmaceuticals Inc. (Press release). 14 October 2020. Retrieved 14 October 2020.

[5] "Inmazeb: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 15 October 2020.

[Drug_Approval_Package-6] "Drug Approval Package: Inmazeb". U.S. Food and Drug Administration. 12 November 2020. Retrieved 23 December 2020.

[7] "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.

[WHO23rd-8] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]